Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593562 | 0.91 | KMT2A (0.43) | MEN1KMT2APPARGALDH1A1HCAR3 | |
| SCHEMBL7592920 | 0.90 | ALDH1A1 (0.42) | MEN1KMT2AEPHX2PPARGALDH1A1 | |
| SCHEMBL7595990 | 0.90 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1HCAR3GAA | |
| SCHEMBL7592996 | 0.82 | POLB (0.53) | MEN1KMT2AL3MBTL1MAPTALDH1A1 | |
| SCHEMBL7596953 | 0.81 | HCAR3 (0.48) | KMT2AL3MBTL1ALDH1A1HCAR3GAA | |
| SCHEMBL7591621 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2AMAPTALDH1A1HCAR3 | |
| SCHEMBL7595228 | 0.81 | KMT2A (0.40) | MEN1KMT2AEPHX2MAPTALDH1A1 | |
| SCHEMBL7593606 | 0.79 | HCAR3 (0.46) | MEN1KMT2AMAPTALDH1A1HCAR3 | |
| SCHEMBL7597821 | 0.79 | MME (0.44) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL7590085 | 0.79 | L3MBTL1 (0.42) | MEN1KMT2AL3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | MEN1 1677/4885KMT2A 1590/4885EPHX2 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.